Cel-Sci Corporation - CVM

Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.69 Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: 4:00pm Bid x Ask Size: N/A
Change: up arrow +0.0200 (+2.99%) Day's Range: 0.67 - 0.72
Prev Close: 0.6700 52wk Range: 0.53 - 1.90
Open: 0.6800 P/E (ttm): N/A
Volume: 623,667 EPS (ttm): -0.53
spacer [Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
Thu, 23 Oct 2014 19:48:59 GMT
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
Wed, 22 Oct 2014 10:01:41 GMT
NEW STORY CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants
Tue, 21 Oct 2014 14:32:42 GMT
[at noodls] - CEL-SCI CORPORATION PRICES $6 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Vienna, VA, October 21, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that ...
NEW STORY CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
Tue, 21 Oct 2014 14:32:42 GMT
[at noodls] - CEL-SCI CORPORATION TO RAISE $1 MILLION IN REGISTERED DIRECT OFFERING Vienna, VA, October 21, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, has agreed to sell common stock ...
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
Tue, 21 Oct 2014 13:42:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, has agreed to sell common stock and warrants in a registered direct offering to European investors at a combined price of $0.76 for aggregate gross proceeds of a little over $1 million.
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants
Tue, 21 Oct 2014 13:15:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, today announced that it has priced a “best efforts” underwritten public offering of common stock and warrants at a combined price of $0.76 for aggregate gross proceeds of $6 million, prior to deducting underwriting commissions and offering expenses and excluding the exercise of any warrants.
NEW STORY CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants
Mon, 20 Oct 2014 21:51:34 GMT
[at noodls] - CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Vienna, VA, October 20, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that ...
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants
Mon, 20 Oct 2014 20:30:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants in an underwritten public offering.
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial
Fri, 03 Oct 2014 13:15:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer
Coverage Initiation Report Focuses on CEL-SCI Corporation
Wed, 01 Oct 2014 15:32:41 GMT
[Marketwired] - CEL-SCI Corporation is the subject of an in-depth initiation coverage report by Acceleron Equity Research.
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
Mon, 29 Sep 2014 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced the first volunteer patient has been enrolled and administered Multikine* in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego .
University of Minnesota Masonic Cancer Center Joins CEL-SCI’s Phase III Head & Neck Cancer Trial
Wed, 10 Sep 2014 12:45:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that the University of Minnesota’s Masonic Cancer Center has becomes the 7th clinical site in the U.S. to join its Phase III hea
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
Wed, 03 Sep 2014 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* during August 2014.
CEL SCI CORP Financials
Tue, 19 Aug 2014 17:04:10 GMT
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada
Tue, 19 Aug 2014 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* has added Centre Hospitalier Universitaire de Québec ’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America.
CEL SCI CORP Files SEC form 10-Q, Quarterly Report
Fri, 08 Aug 2014 20:15:39 GMT
CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results
Fri, 08 Aug 2014 20:10:00 GMT
[Business Wire] - CEL-SCI Corporation today reported financial results for the quarter ended June 30, 2014.
CEL SCI CORP Files SEC form 8-K, Change in Directors or Principal Officers
Thu, 07 Aug 2014 18:31:33 GMT
Cel-Sci's Enrollment Math Doesn't Add up
Fri, 01 Aug 2014 15:11:00 GMT
CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial
Fri, 01 Aug 2014 12:45:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .